Galectin-3, a Kupffer cell/macrophage-derived lectin, is required for TGFβ-mediated activation of HSCs (59), and an inhibitor of Galectin 3 (GR-MD-02; NCT02462967) is also being evaluated as an anti-fibrotic drug in a phase 2b trial in NASH patients. Here, LGALS3 is linked to metabolic dysfunction-associated steatohepatitis.